Climb Bio partner Mabworks doses first patient in China Phase 2 IgA nephropathy trial
CLYM•Phase 2 trial starts patient dosing in China
A Phase 2 trial in China dosed its first patient with immunoglobulin A nephropathy in a study run with Climb Bio.
- No clinical results were reported; the update signals the program has moved into active patient treatment.
- Beijing Mabworks announced the milestone on Aug. 13, 2026.
